Michelle Mellion

Michelle is Senior Vice President, Head of Clinical Development at PepGen. She has extensive experience in the evaluation and treatment of neuromuscular and neurological indications, having worked in both academic and commercial settings. Most recently, she served in roles of increasing responsibility, including Executive Medical Director, at Fulcrum Therapeutics where she led the design and implementation of Phase I/II/III clinical trials for the company’s novel treatment of facioscapulohumeral muscular dystrophy. While leading clinical development efforts at Fulcrum, she also worked as an Attending Physician affiliated with Tufts Medical Center, specializing in Neurology as a member of their Pediatrics department. Michelle has also held leadership roles at Vertex Pharmaceuticals and Biogen, where she facilitated the preclinical translation and clinical development of treatments for pain, multiple sclerosis, and other indications. Prior to joining Biogen, Michelle was an Attending Neurologist in the Muscular Dystrophy Association (MDA) clinic and Attending Physician and Assistant Professor of Neurology at Alpert Medical School, Brown University. Michelle completed her residency at Brown Medical School, received her M.D. from the Wake Forest University School of Medicine, and earned her B.A. in Molecular Biology from Colgate University.